Kinetics of group IB and IIA phospholipase A2 during low-volume continuous hemodiafiltration in severe acute pancreatitis

Artificial Organs

Volumn 31, Issue 5, 2007, Pages 395-401

  Suzuki, Masaharu ^a   Okahisa, Toshiya ^a   Sogabe, Masahiro ^a   Iwaki, Hiroshi ^a   Okita, Yoshio ^a   Ohnishi, Yoshiaki ^a   Ito, Susumu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Continuous hemodiafiltration; Group IB PLA2; Kinetics; Phospholipase A2; Severe acute pancreatitis

Indexed keywords

ACUTE PANCREATITIS; CONTINUOUS HEMODIAFILTRATION; GROUP IB PHOSPHOLIPASE A2; HEMODIAFILTRATION; HEMOFILTERS; PHOSPHOLIPASE A2; PLASMA CONCENTRATION; SEVERE ACUTE PANCREATITIS; WASTE FLUID;

KINETICS;

PHOSPHOLIPASE A2; POLYSULFONE;

ACUTE PANCREATITIS; ADSORPTION; ADULT; AGED; BLOOD FLOW VELOCITY; BLOOD LEVEL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTINUOUS HEMODIAFILTRATION; CONTROLLED STUDY; ENZYME KINETICS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

EID: 34247603631     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2007.00398.x     Document Type: Conference Paper

References (25)

1. Swaroop VS, Chari ST, Clain JE. Severe acute pancreatitis. JAMA 2004 291:2865 8.
2. Bhatia M. Novel therapeutic targets for acute pancreatitis and associated multiple organ dysfunction syndrome. Curr Drug Targets Inflamm Allergy 2002 1:343 51.
3. Blinzler L, Hausser J, Bodeker H, Zaune U, Martin E, Gebhardt C. Conservative treatment of severe necrotizing pancreatitis using early continuous venovenous hemofiltration. Contrib Nephrol 1991 93:234 6.
4. Yekebas EF, Treede H, Knoefel WT, Bloechle C, Fink E, Izbicki JR. Influence of zero-balanced hemofiltration on the course of severe experimental pancreatitis in pigs. Ann Surg 1999 229:514 22.
5. Oda S, Hirasawa H, Shiga H, Nakanishi K, Matsuda K, Nakamura M. Continuous hemofiltration/ hemodiafiltration in critical care. Ther Apher 2002 6:193 8.
6. Wang H, Li WQ, Zhou W, Li N, Li JS. Clinical effects of continuous high volume hemofiltration on severe acute pancreatitis complicated with multiple organ dysfunction syndrome. World J Gastroenterol 2003 9:2096 9.
7. Jiang HL, Xue WJ, Li DQ, et al. Influence of continuous veno-venous hemofiltration on the course of acute pancreatitis. World J Gastroenterol 2005 11:4815 21.
8. Hietaranta A, Kemppainen E, Puolakkainen P, et al. Extracellular phospholipase A2 in relation to systemic inflammatory response syndrome (SIRS) and systemic complications in severe acute pancreatitis. Pancreas 1999 18:385 91.
9. Tcholakov O, Uhl W, Schmitter N, et al. Role of phospholipase A2 in acute pancreatitis. In:Büchler MW, Uhl W, Friess H, Malfertheiner P, eds. Novel Concepts in Biology and Therapy. Berlin, Germany:Blackwell Science, 1999 109 19.
10. Nevalainen TJ, Eerola LI, Rintala E, Laine VJ, Lambeau G, Gelb MH. Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum. Biochim Biophys Acta 2005 1733:210 23.
11. Nevalainen TJ, Eskola JU, Aho AJ, Havia VT, Lövgren TNE, Näntf V. Immunoreactive phospholipase A2 in serum in acute pancreatitis and pancreatic cancer. Clin Chem 1985 31:1116 20.
12. Büchler M, Malfertheiner P, Schädlich H, Nevalainen T, Friess H, Beger HG. Role of phospholipase A2 in human acute pancreatitis. Gastroenterology 1989 97:1521 6.
13. Nevalainen TJ, Haapamäki MM, Grfnroos JM. Review. Roles of secretory phospholipases A2 in inflammatory diseases and trauma. Biochim Biophys Acta 2000 1488:83 90.
14. Nevalainen TJ. Serum phospholipase A2 in inflammatory diseases. Clin Chem 1933 39:2453 9.
15. Terao Y, Hashimoto S, Nakamura H, et al. Is circulatory phospholipase A2 removed by continuous hemodiafiltration in septic acute renal failure? J Jpn Soc Intensive Care Med 1998 5:385 8.
16. Hirasawa H. Severe acute pancreatitis. In:Hirasawa H, ed., Acute Blood Purification. Tokyo:Sogo-igaku Co., Ltd. Press, 1994 115 26 (in Japanese).
17. Ogawa M, Hirota M, Hayakawa T, et al. Development and use of a new staging system for severe acute pancreatitis based on a nationwide survey in Japan. Pancreas 2002 25:325 30.
18. Ueda A, Yamauchi A, Misaki A, Ueki K, Kono M. Radioimmunoassay of pancreatic phospholipase A2 in human serum. Rinsho Byori 1989 37:561 5 (in Japanese).
19. Matsuda Y, Ogawa M, Sakamoto K, et al. Development of a radioimmunoassay for human group-II phospholipase A2 and demonstration of postoperative elevation. Enzyme 1991 45:200 8.
20. Takeda K, Matuno S, Sunamura M, Kakugawa Y. Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotising pancreatitis. Am J Surg 1996 174:394 8.
21. Luiten EJ, Hop WC, Lange JF, Bruining HA. Controlled clinical trial of selective decontamination for the treatment of severe acute pancreatitis. Ann Surg 1995 222:57 65.
22. Nakamura H, Kim DK, Philbin DM, et al. Heparin-enhanced plasma phospholipase A2 activity and prostacyclin synthesis in patients undergoing cardiac surgery. J Clin Invest 1995 95:1062 70.
23. Okita Y, Okahisa T, Sogabe M, Suzuki M, Ohnishi Y, Ito S. Low volume continuous hemodiafiltration with nafamostat mesilate increases trypsin clearance without decreasing plasma trypsin concentration in severe acute pancreatitis. ASAIO J 2007 53:207 12.
24. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J. Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med 1997 23:878 84.
25. Akizawa T, Sato M, Kitaoka T, et al. The usefulness of the multi-enzyme inhibitor, nafamostat mesilate, in high bleeding risk hemodialysis. Proc Eur Dial Transplant Assoc 1985 22:334 8.